الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 110 |  |  |
| | | from | 110 | | |
Abstract
Alendronate Sodium (ALDS) Is The Drug Of Choice For Treatment Of Osteoporosis. However, 50% Of The Osteoporotic Patients Cease The Treatment Within The First Year Due To Its Potential Side Effect On The Gastrointestinal Tract (GIT).
The Current Study Aimed To Utilize Nanotechnology For Development Of A Nano-Oral Liposomal Preparation Containing Biodegradable Polymer (Starch) That Increases Drug Stability As Well As Gastric Tolerance. Nanoliposomes Of ALDS Were Prepared Using Different Concentrations Of Solubilized Starch (0.1 - 0.5 Gm ) By Thin Film Hydration Method. A New Method Of ALDS Quantitative Determination Was Used. The selected Formula Was Visualized Using TEM, In Vitro Release Studies And Stability Study Was Also Carried Out. Furthermore, Ulcerogenicity Studies Were Performed To Compare Between The Optimum Prepared Formula And A Standard Nonliposomal ALDS.
Six Nano-Oral Liposomal Formulations Were Prepared With Zeta Potential Values Ranging from -12 Mv To -39 Mv And Particle Sizes Ranging from 94 Nm To 298 Nm. The Encapsulation Efficiency Demonstrated That The Amount Of ALDS Entrapped Within Liposomes Increased With Increasing Starch Concentration. The Stability Studies Confirmed The Role Of Starch In Increasing The Stability Of The Prepared Liposomes. In Vitro Release Studies Demonstrated A Relative Delay In ALDS Release from The Liposome Core. Ulcerogenicity Studies Proved That The Prepared Formula Has A Significant Gastric Tolerance.